A new clinical study has demonstrated significant benefits of Cerebrolysin as an adjuvant therapy following mechanical thrombectomy in patients with acute ischemic stroke (AIS), potentially opening new avenues for improving post-stroke recovery outcomes.
The prospective study, involving 150 patients with cardioembolic acute ischemic stroke, showed that patients receiving Cerebrolysin achieved substantially better functional outcomes compared to those who received standard care alone. The treatment group demonstrated a remarkable 64% rate of favorable outcomes at 90 days, nearly double the 34.7% observed in the control group.
Treatment Protocol and Study Design
The investigation enrolled 75 patients who received daily doses of 30 ml Cerebrolysin for 14 days, with treatment initiated within eight hours following mechanical thrombectomy. These patients were compared against a matched historical control group of 75 patients who underwent mechanical thrombectomy ± recombinant tissue plasminogen activator (rt-PA) without Cerebrolysin treatment.
All enrolled patients had a National Institutes of Health Stroke Scale (NIHSS) score of ≥10, ensuring the study focused on moderate to severe stroke cases. The researchers employed propensity score matching to ensure comparable baseline characteristics between the groups.
Significant Clinical Improvements
The study's primary endpoint, measured by the modified Rankin Scale (mRS) at day 90, showed compelling results. Patients in the Cerebrolysin group demonstrated:
- 64% achieved favorable outcomes (mRS 0-2) compared to 34.7% in the control group
- Consistently lower NIHSS scores throughout all study visits
- Significantly reduced rates of hemorrhagic transformation (20% vs. 57.3%)
Safety Profile and Hemorrhagic Risk
A particularly noteworthy finding was the substantial reduction in hemorrhagic transformation risk among treated patients. The logistic regression analysis revealed that patients achieving favorable mRS scores were significantly less likely to experience hemorrhagic transformation (odds ratio = 2.75, 95% confidence interval = 1.17, 6.45; p = 0.002).
The treatment regimen proved to be well-tolerated, with no significant safety concerns reported during the study period. This safety profile, combined with the marked improvement in outcomes, suggests a promising role for Cerebrolysin in post-thrombectomy care.
Clinical Implications
These findings represent a potentially significant advancement in the management of acute ischemic stroke patients undergoing mechanical thrombectomy. While endovascular recanalization therapy has shown considerable efficacy in AIS treatment, not all patients achieve optimal long-term outcomes. The addition of Cerebrolysin to the treatment protocol may help address this therapeutic gap.
The researchers note that while these results are promising, further studies are needed to confirm these findings and potentially establish Cerebrolysin as a standard adjuvant therapy in post-thrombectomy care. The significant reduction in hemorrhagic transformation risk, combined with improved functional outcomes, warrants particular attention in future investigations.
